Cannabis Medicine Vital to Epilepsy Care, Physician Argues

The Clinical Case for Cannabinoids in Seizure Control

Cannabidiol (CBD) has demonstrated efficacy in reducing seizure frequency in patients with Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of childhood epilepsy. Dr. Kalcheff-Korn pointed to FDA-approved Epidiolex as the clearest proof of concept. The drug's 2018 approval marked the first time federal regulators recognized a cannabis-derived medication for any indication.

The physician's argument centers on a population of epilepsy patients—estimated at 30% of all cases—whose seizures resist first-line treatments. For these patients, cannabinoid therapy often represents the difference between uncontrolled daily seizures and functional quality of life.

Clinical trials have shown that CBD can reduce seizure frequency by 40% or more in treatment-resistant cases. The mechanism involves modulation of GABA and glutamate signaling, though researchers continue to map the full pharmacology.

Access Barriers Persist Despite Evidence

Insurance coverage for cannabis-based epilepsy treatments remains inconsistent, and state-level medical marijuana programs impose regulatory friction that delays patient access. Dr. Kalcheff-Korn criticized the gap between clinical evidence and reimbursement policy, noting that families often pay out-of-pocket for treatments that peer-reviewed literature supports.

Massachusetts allows medical cannabis for epilepsy under its qualifying conditions list, but the state's program requires physician certification, patient registration, and dispensary sourcing. That process can take weeks or months. Seizures don't wait.

Epidiolex, as an FDA-approved pharmaceutical, bypasses those barriers but costs upward of $30,000 annually without insurance. Generic CBD products lack the dosing precision and quality controls neurologists require for epilepsy management.

The Policy Argument for Expanded Medical Access

Dr. Kalcheff-Korn's core claim is straightforward: cannabinoid medicines should be treated as standard-of-care options for refractory epilepsy, not experimental or fringe therapies. The physician called for streamlined state medical programs, broader insurance coverage, and continued federal research into cannabinoid mechanisms.

His argument arrives as DEA's proposed rescheduling of cannabis to Schedule III remains under review. Rescheduling wouldn't directly affect FDA-approved drugs like Epidiolex, but it could ease research barriers and reduce stigma around cannabinoid prescribing.

For full background on this story, see the CannIntel topic hub on cannabis for epilepsy treatment.

Neurologists who prescribe cannabinoid therapies report that patient outcomes often justify the administrative burden, but the current patchwork of state and federal rules creates friction that delays care. The next step is likely to be insurance formulary inclusion and physician education on dosing protocols.